Clinical Research Trials
Gastro Florida offers clinical research trials in which volunteers participate and receive a trial treatment for a particular condition while under supervision. There are multiple advantages for participating in a clinical research trial. They include:
- Access to the latest treatments before they are widely available
- Therapeutic options when other methods have not worked
- Playing an active role in your health care
- Help others by contributing to science and research
- Research may lead to better treatment of their condition
- No monetary cost to the patient
For more information about the active trials listed below, please e-mail This email address is being protected from spambots. You need JavaScript enabled to view it. or call (727) 347-0005 and choose option 3.
Active Trials
Click on a condition below to see active trials
GA29144: This is a multicenter, Phase 3, double-blind, placebo-controlled study evaluating the efficacy, safety, and tolerability of etrolizumab compared with placebo during induction and maintenance treatment of moderate to severely active CD in participants who are refractory or intolerant to corticosteroids (CS), immunosuppressants (IS), or anti-tumor necrosis factors (anti-TNFs) or have inadequate response to anti-tumor necrosis factor (TNF-IR). Participants who enroll on the basis of refractory or intolerance to CS and/or IS may have been previously exposed to anti-TNFs or be naïve to anti-TNFs. The study period will consist of Screening Phase (up to 35 days) plus (+) 14-week Induction Phase + 52-week Maintenance Phase + 12-week Safety Follow-up Phase. At Week 14 (end of Induction Phase), participants achieving decrease of 70 points in Crohn's Disease Activity Index (CDAI) from baseline (CDAI-70 response) without the use of rescue therapy will continue to the Maintenance Phase.
B7981007: The objectives of this study are to evaluate the efficacy, safety, tolerability, pharmacokinetics, and pharmacodynamics of PF-06651600 (200 mg for 8 weeks followed by 50 mg for 4 weeks) dosed once daily and PF-06700841 (60 mg for 12 weeks) dosed once daily during an induction period of 12 weeks, followed by an open label extension period at doses of 50 mg and 30 mg of PF 06651600 and PF 06700841, respectively, for 52 weeks.
RPC01-3201: This is a Phase 3, randomized, double-blind, placebo-controlled study to explore the effect of oral ozanimod as an induction treatment for subjects with moderately to severely active Crohn's Disease.
D5271C00002 301: A 52-week, multicenter, randomized, double-blind, double-dummy, placebo and active-controlled, operationally seamless phase 2b/3, parallel-group study to assess the efficacy and safety of brazikumab in participants with moderately to severely active Crohn's Disease.
APD334-202: A multicenter, randomized, double-blind, parallel-group study to assess the efficacy and safety of oral etrasimod as induction and maintenance therapy for moderately to severely active Crohn's Disease.
Bristol Myers
IM011023: A Phase 2 randomized, double-blind, placebo-controlled study of the safety and efficacy of BMS-986165 in subjects with moderate to severe Crohn's Disease
16T-MC-AMAM: A phase 3, multicenter, randomized, double-blind, placebo- and active- controlled, treat-through study to evaluate the efficacy and safety of mirikizumab in patients with moderately to severely active Crohn's Disease.
206 EOE: A Phase 2 randomized, double-blind, placebo-controlled study to assess the safety and efficacy of etrasimod in adult subjects with eosinophilic esophagitis.
CC-93538-EE-001: A phase 3, multicenter, multinational, randomized, double-blind, placebo-controlled induction and maintenance study to evaluate the efficacy and safety of CC-93538 in adult and adolescent participants with eosinophilic esophagitis.
C2541013: A phase 2, randomized, double-blind, double-dummy, placebo-controlled, dose-ranging, dose-finding, parallel group study to assess efficacy and safety of pf-06865571 (DGAT2i) alone and when coadministered with pf-05221304 (ACCi) in adult participants with biopsy-confirmed nonalcoholic steatohepatitis and fibrosis stage 2 or 3.
Please check back at another time.
AstraZeneca
PLC D5271C00001 EXT 201: A 52-week, multicenter, randomized, double-blind, double-dummy, placebo and active-controlled, operationally seamless phase 2b/3, parallel-group study to assess the efficacy and safety of brazikumab in participants with moderately to severely active ulcerative colitis.
B7981005: The purpose of this study is to determine whether PF-06651600 and PF-06700841 are effective in treatment of moderate to severe ulcerative colitis.
APD334-301: The purpose of this study is to determine whether etrasimod is a safe and effective treatment for moderately to severely active ulcerative colitis.
2/B7541007: A phase 2b, multicenter, randomized, double-blind, placebo-controlled dose-ranging study to evaluate the efficacy, safety, and pharmacokinetics of PF-06480605 in adult participants with moderate to severe ulcerative colitis.
210: A randomized, double-blind, placebo-controlled, 52-week study to assess the efficacy and safety of etrasimod in subjects with moderately active ulcerative colitis.
VE303-002: This study will evaluate the safety and efficacy of VE303 for participants with recurrent Clostridium difficile infection (rCDI).
Seres
013: Ecospor IV: an open-label extension of study seres-012 and open-label program for evaluating ser-109 in adult subjects with recurrent Clostridioides difficile infection (rCDI)
Please check back at another time.
